Diffuse midline glioma with novel, potentially targetable, fusion.

TitleDiffuse midline glioma with novel, potentially targetable, fusion.
Publication TypeJournal Article
Year of Publication2020
AuthorsZanazzi G, Liechty BL, Pendrick D, Krasnozhen-Ratush O, Snuderl M, Allen JC, Garvin JH, Mansukhani MM, Roth KA, Hsiao SJ
JournalCold Spring Harb Mol Case Stud
Volume6
Issue5
Date Published2020 10
ISSN2373-2873
KeywordsBrain Neoplasms, Child, Glioma, Humans, In Situ Hybridization, Fluorescence, Male, Mutation, Receptor, Fibroblast Growth Factor, Type 2, Vesicular Transport Proteins, Whole Exome Sequencing
Abstract

We report a case of a slow-growing, diffuse, infiltrating glioma in the right brainstem of a 9-yr-old boy. The tumor was negative by immunohistochemical staining for histone H3 K27M, BRAF V600E, and IDH1 R132H mutations. Fluorescence in situ hybridization did not reveal a BRAF duplication. Genomic profiling of the tumor, by DNA methylation array and cancer whole-exome and transcriptome sequencing, was performed. This analysis showed copy-number alterations, including gains of several chromosomes. In addition, a novel fusion involving the first 17 exons of fused to exon 2 of was identified. This novel fusion is predicted to result in activation of fibroblast growth factor receptor (FGFR) signaling and is potentially targetable using FGFR inhibitors. This tumor expands the spectrum of pediatric diffuse gliomas.

DOI10.1101/mcs.a005660
Alternate JournalCold Spring Harb Mol Case Stud
PubMed ID32839179
PubMed Central IDPMC7552930
Related Faculty: 
Benjamin L. Liechty, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700